Answers are grounded in this paper and cite their sources.
In conclusion, a negative axillary ultrasound generally excludes the presence of pN2-pN3 disease. An axillary ultrasound cannot accurately differentiate between pN1 and pN2-pN3. It could be argued that the standard performance of an axillary ultrasound in breast cancer patients is questionable; multidisciplinary discussion could guide decisions on the use of axillary ultrasound for the individual patient.
No takes yet. Share an insight, caveat, or question.
Schipper et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: